The development of a selective cyclin-dependent kinase inhibitor which demonstrates anti-tumor activity

Normal progression through the cell cycle requires the sequential action of cyclin-dependent kinases CDK1, CDK2, CDK4 and CDK6. Direct or indirect deregulation of CDK activity is a feature of almost all cancers, and has led to the development of CDK inhibitors as anti-cancer agents. The CDK-activati...

詳細記述

保存先:
書誌詳細
主要な著者: Ali, Simak, Heathcote, Dean A., Kroll, Sebastian H. B., Jogalekar, Ashutosh S., Scheiper, Bodo, Patel, Hetal, Brackow, Jan, Siwicka, Alekasandra, Fuchter, Matthew J., Periyasamy, Manikandan, Tolhurst, Robert S., Kanneganti, Seshu K., Snyder, James P., Liotta, Dennis C., Aboagye, Eric O., Barrett, Anthony G. M., Coombes, R. Charles
フォーマット: Artigo
言語:Inglês
出版事項: 2009
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2875168/
https://ncbi.nlm.nih.gov/pubmed/19638587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-0301
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料